Staging for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Utility of Incorporating Biologic Factors

被引:4
|
作者
Yi, Min [1 ]
Lin, Heather [2 ]
Bedrosian, Isabelle [1 ]
Shen, Yu [2 ]
Hunt, Kelly K. [1 ]
Chavez-MacGregor, Mariana [3 ,4 ]
King, Tari A. [5 ,6 ]
Mittendorf, Elizabeth A. [5 ,6 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Breast Surg Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Hlth Serv Res, Houston, TX 77030 USA
[5] Brigham & Womens Hosp, Dept Surg, Div Breast Surg, 75 Francis St, Boston, MA 02115 USA
[6] Dana Farber Brigham & Womens Canc Ctr, Breast Oncol Program, Boston, MA 02215 USA
关键词
SURVIVAL; VALIDATION; BURDEN;
D O I
10.1245/s10434-019-07983-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. The American Joint Committee on Cancer (AJCC) breast cancer pathological prognostic stage, which incorporates biologic factors, was developed using data from patients undergoing upfront surgery, and its application in patients receiving neoadjuvant chemotherapy (NAC) is unknown. We previously developed the Neo-Bioscore, incorporating clinical and pathological TNM categories with biologic factors, to improve the prognostic stratification of NAC patients. Objective. This study was undertaken to evaluate the use of available staging models incorporating biologic factors in NAC patients. Methods. Patients treated with NAC between 2005 and 2012 at MD Anderson (n = 2363) were staged using the Neo-Bioscore and the AJCC 8th edition: (1) clinical anatomic stage; (2) pathological anatomic stage; (3) clinical prognostic stage; and (4) pathological prognostic stage. Five-year disease-specific survival (DSS) and overall survival (OS) rates, along with Harrell's concordance index (C-index), were estimated. A National Cancer Database (NCDB) cohort (n = 12,887) treated with NAC between 2010 and 2013 was used for validation. Results. In the MD Anderson cohort, staging systems incorporating biologic factors better predicted DSS (bias-corrected C-index: pathological prognostic stage = 0.8026; Neo-Bioscore = 0.7483) and OS (bias-corrected C-index: pathological prognostic stage = 0.7780; Neo-Bioscore = 0.7260) than those using anatomic factors only. Similar results were seen in the NCDB cohort. In pairwise comparisons, the pathological prognostic stage was significantly better (p < 0.0001) than other staging systems in all comparisons except for OS in the NCDB cohort, where it was not significantly different than the Neo-Bioscore (p = 0.2). Conclusion. Biologic factors are important for determining prognosis in patients receiving NAC. These data indicate that the 8th edition AJCC pathological prognostic stage is applicable in these patients.
引用
收藏
页码:359 / 366
页数:8
相关论文
共 50 条
  • [1] Staging for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Utility of Incorporating Biologic Factors
    Min Yi
    Heather Lin
    Isabelle Bedrosian
    Yu Shen
    Kelly K. Hunt
    Mariana Chavez-MacGregor
    Tari A. King
    Elizabeth A. Mittendorf
    Annals of Surgical Oncology, 2020, 27 : 359 - 366
  • [2] Systemic staging in breast cancer patients receiving neoadjuvant chemotherapy
    Lattimore, Courtney
    Gabriella, Squeo
    Brenin, Christiana
    Showalter, Shayna
    Millard, Trish
    CANCER RESEARCH, 2023, 83 (05)
  • [3] Staging for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Utility of the 8th Edition AJCC Staging System
    Yi, M.
    Hunt, K.
    Bedrosian, I.
    Chavez-MacGregor, M.
    Mittendorf, E. A.
    ANNALS OF SURGICAL ONCOLOGY, 2018, 25 : S25 - S26
  • [4] Axillary staging and treatment in breast cancer patients receiving neoadjuvant chemotherapy
    van der Heiden-van der Loo, M.
    de Munck, L.
    Sonke, G. S.
    van Dalen, T.
    van Diest, P. J.
    van den Bongard, H. J. G. D.
    Peeters, P. H. M.
    Rutgers, E. J. T.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S1 - S2
  • [5] Role of staging in breast cancer patients receiving neoadjuvant chemotherapy (NACT)
    Lau, Karen
    Dodwell, David
    Sharma, Nisha
    BREAST CANCER RESEARCH, 2018, 20
  • [6] Bioscore: A novel staging system for breast cancer patients receiving neoadjuvant chemotherapy
    Mittendorf, E. A.
    Vila, J.
    Tucker, S. L.
    Chavez-MacGregor, M.
    Smith, B. D.
    Symmans, W. F.
    Sahin, A. A.
    Hortobagyi, G. N.
    Hunt, K. K.
    CANCER RESEARCH, 2016, 76
  • [7] The Utility of an Extensive Postchemotherapy Staging Evaluation in Patients Receiving Neoadjuvant Chemotherapy for Bladder Cancer
    Reese, Adam C.
    Ball, Mark W.
    Gandhi, Nilay
    Gorin, Michael A.
    Netto, George J.
    Bivalacqua, Trinity J.
    Schoenberg, Mark P.
    UROLOGY, 2014, 84 (02) : 358 - 363
  • [8] Staging for Breast Cancer With Internal Mammary Lymph Nodes Metastasis: Utility of Incorporating Biologic Factors
    Lian, Chen-Lu
    Zhang, Hai-Yan
    Wang, Jun
    Lei, Jian
    Hua, Li
    Chen, Yong-Xiong
    Wu, San-Gang
    FRONTIERS IN ONCOLOGY, 2021, 10
  • [9] Staging the Axilla With Ultrasound and Core Biopsy for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
    Venditti, Charis A.
    Tower, Amelia
    Erb, Kathleen
    Julian, Thomas B.
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 : 111 - 112
  • [10] The Utility of an Extensive Postchemotherapy Staging Evaluation in Patients Receiving Neoadjuvant Chemotherapy for Bladder Cancer REPLY
    Reese, Adam C.
    Bivalacqua, Trinity J.
    Schoenberg, Mark P.
    UROLOGY, 2014, 84 (02) : 364 - 364